Idarucizumab for the Reversal of Dabigatran

Annals of Emergency Medicine

Volumn 69, Issue 5, 2017, Pages 554-558

  Gottlieb, Michael ^a   Khishfe, Basem ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; IDARUCIZUMAB; ANTIDOTE; ANTITHROMBIN; MONOCLONAL ANTIBODY;

ANTICOAGULATION; BINDING AFFINITY; BLEEDING; BLOOD CLOTTING; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED PRACTICE; HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ADOLESCENT; ADULT; AGED; ANTAGONISTS AND INHIBITORS; DOUBLE BLIND PROCEDURE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIDOTES; ANTITHROMBINS; CLINICAL TRIALS, PHASE I AS TOPIC; DABIGATRAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 85009812004     PISSN: 01960644     EISSN: 10976760     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2016.11.025     Document Type: Review

References (20)

1. 1 Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
2. 2 Alikhan, R., Rayment, R., Keeling, D., et al. The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emerg Med J 31 (2014), 163–168.
3. 3 Honickel, M., Braunschweig, T., van Ryn, J., et al. Prothrombin complex concentrate is effective in treating the anticoagulant effects of dabigatran in a porcine polytrauma model. Anesthesiology 123 (2015), 1350–1361.
4. 4 Singh, T., Maw, T.T., Henry, B.L., et al. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol 8 (2013), 1533–1539.
5. 5 Schiele, F., van Ryn, J., Canada, K., et al. A specific antidote for dabigatran: functional and structural characterization. Blood 121 (2013), 3554–3562.
6. 6 Glund, S., Stangier, J., van Ryn, J., et al. Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib study. Clin Pharmacokinet, 2016 http://dx.doi.org/10.1007/s40262-016-0417-0.
7. 7 Grottke, O., van Ryn, J., Spronk, H.M., et al. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. Crit Care, 18, 2014, R27.
8. 8 Grottke, O., Honickel, M., van Ryn, J., et al. Idarucizumab, a specific dabigatran reversal agent, reduces blood loss in a porcine model of trauma with dabigatran anticoagulation. J Am Coll Cardiol 66 (2015), 1518–1519.
9. 9 Honickel, M., Treutler, S., van Ryn, J., et al. Reversal of dabigatran anticoagulation ex vivo: porcine study comparing prothrombin complex concentrates and idarucizumab. Thromb Haemost 113 (2015), 728–740.
10. 10 Na, S.Y., Mracsko, E., van Ryn, J., et al. Idarucizumab improves outcome in murine brain hemorrhage related to dabigatran. Ann Neurol 78 (2015), 137–141.
11. 11 Glund, S., Moschetti, V., Norris, S., et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 113 (2015), 943–951.
12. 12 Glund, S., Stangier, J., Schmohl, M., et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 386 (2015), 680–690.
13. 13 Glund, S., Stangier, J., van Ryn, J., et al. Restarting dabigatran etexilate 24 h after reversal with idarucizumab and redosing idarucizumab in healthy volunteers. J Am Coll Cardiol 67 (2016), 1654–1656.
14. 14 Pollack, C.V. Jr., Reilly, P.A., Eikelboom, J., et al. Idarucizumab for dabigatran reversal. N Engl J Med 373 (2015), 511–520.
15. 15 Food and Drug Administration. Idarucizumab. Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm467396.htm. Accessed October 7, 2016.
16. 16 European Medicines Agency. EPAR summary for the public, Praxbind. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003986/WC500197464.pdf. Accessed October 7, 2016.
17. 17 Frontera, J.A., Lewin, J.J. 3rd, Rabinstein, A.A., et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 24 (2016), 6–46.
18. 18 Pollack, C.V. Jr., Reilly, P.A., Bernstein, R., et al. Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 114 (2015), 198–205.
19. 19 Eikelboom, J.W., Quinlan, D.J., van Ryn, J., et al. Idarucizumab: the antidote for reversal of dabigatran. Circulation 132 (2015), 2412–2422.
20. 20 Elia J. Dabigatran-reversal agent price set. Available at: http://www.jwatch.org/fw110754/2015/10/20/dabigatran-reversal-agent-price-set. Accessed October 7, 2016.